Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Hims & Hers Health, Inc. (HIMS) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question. Hims & Hers Health, Inc. is a member of our Medical group, which includes 1026 different companies and currently sits at #5 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Hims & Hers Health, Inc. is currently sporting a Zacks Rank of #1 (Strong Buy). Within the past quarter, the Zacks Consensus Estimate for HIMS' full-year earnings has moved 100.6% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger. Based on the most recent data, HIMS has returned 133.5% so far this year. At the same time, Medical stocks have gained an average of 5.2%. As we can see, Hims & Hers Health, Inc. is performing better than its sector in the calendar year. One other Medical stock that has outperformed the sector so far this year is Novo Nordisk (NVO). The stock is up 37.6% year-to-date. The consensus estimate for Novo Nordisk's current year EPS has increased 3.6% over the past three months. The stock currently has a Zacks Rank #2 (Buy). Looking more specifically, Hims & Hers Health, Inc. belongs to the Medical Info Systems industry, a group that includes 43 individual stocks and currently sits at #99 in the Zacks Industry Rank. On average, this group has lost an average of 19.4% so far this year, meaning that HIMS is performing better in terms of year-to-date returns. In contrast, Novo Nordisk falls under the Large Cap Pharmaceuticals industry. Currently, this industry has 12 stocks and is ranked #84. Since the beginning of the year, the industry has moved +21.5%. Going forward, investors interested in Medical stocks should continue to pay close attention to Hims & Hers Health, Inc. and Novo Nordisk as they could maintain their solid performance. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Hims & Hers Health, Inc. (HIMS):Free Stock Analysis Report Novo Nordisk A/S (NVO):Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research
Are Medical Stocks Lagging Hims & Hers Health (HIMS) This Year?
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...